Table 1:

Current evidence about the efficacy of Jak-inhibitors in uveitis.

Reference and number	# of patients and disease	JAK-I treatment	Previous treatment	Effect on uveitis	Effect on systemic disease
Miserocchi et al., Clinical Rheumatology, 2020 (12)	4 adults with JIA-U	3 baricitinib (1 pt: 5mg/daily 2 pts: 4 mg/daily) 1 pt: tofacitinib 5mg × 2 / daily	INF, ADA, Leflu, MTX, TCZ, AZA, ABA, RTX	Inactive JIA-U	3 pts: arthritis controlled (1 tofacitinib, 2 baricitinib) 1 pt arthritis not controlled (baricitinib)
Bauermann et al., Ocul Immunol Inflamm 2019 (11)	1 adult JIA-U	1 tofacitinib (5 mg × 2/daily	MTX, ADA, RTX, GOL, INF, cyclosporine, TCZ, MMF	Control of JIA-U	Not reported
Baquet-Walscheid et al., Ocul immunol Inflamm 2022 (10)	1 JIA-U	1 upadacitinib (15 mg/daily)	MTX, cyclosporine, ADA, IFN, TCZ, tofacitinib	Inactive JIA-U	Arthritis inactive

JIA-U Juvenile idiopathic arthritis-associated uveitis, Leflu leflunomide, MTX methotrexate, TCZ tocilizumab, AZA Azathioprine, ABA abatacept, RTX rituximab, MMF mycophenolate mofetil, GOL golimumab, INF infliximab, ADA adalimumab